Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02280473 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 188
- Enrollment target
NCT02280473 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 188 participants.
The verdict
NCT02280473, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 188 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.
Interventions
- DRUG Refresh Optive® Gel Drops
- DRUG REFRESH LIQUIGEL®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2014-11-13 |
| Est. Completion | 2015-03-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02280473
The ClinicalTrials.gov registry entry for NCT02280473 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Refresh Optive® Gel Drops is the first listed.
NCT02280473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02280473 about?
NCT02280473 is a clinical study titled "A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease". This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.
What is the current status of trial NCT02280473?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 188 participants. The study started on 2014-11-13. Estimated completion is 2015-03-16.
What interventions are being tested in trial NCT02280473?
The interventions under investigation include: Refresh Optive® Gel Drops (DRUG), REFRESH LIQUIGEL® (DRUG).
Who is sponsoring clinical trial NCT02280473?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.